COMBINAGE
LIVE

Serial Number

79377556

Owner

Rejuvenate Biomed NV

Attorney

Cheryl L. Burbach

Filing Date

Jul 25, 2023

Add to watchlist:

No watchlists yet
View on USPTO

COMBINAGE Trademark

Serial Number: 79377556 • Registration: 7717676

COMBINAGE is a trademark filed by Rejuvenate Biomed NV on July 25, 2023. The trademark is classified under Class 9 (Computers & Electronics), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Rejuvenate Biomed NV (3 trademarks)

Agoralaan A bis
B-3590 Diepenbeek , BE

Entity Type: 32

Trademark Details

Filing Date

July 25, 2023

Registration Date

March 11, 2025

Published for Opposition

September 17, 2024

Goods & Services

Downloadable artificial intelligence software for data analysis for use in the life sciences research field, pharmaceutical research, medical research, and drug discovery and development; downloadable artificial intelligence software for healthcare for capturing, storing, processing, evaluating and reproducing medical and pharmaceutical data; downloadable artificial intelligence software for data analysis; downloadable software using artificial intelligence for machine learning for healthcare; downloadable health monitoring software for data analysis; downloadable software relating to the medical field for controlling and managing patient medical information; downloadable software for data analysis relating to the pharmaceutical field for drug discovery and development; downloadable bioinformatics software for drug discovery and development, for controlling and managing patient medical information; electronic databases, namely, downloadable databases and electronic database recorded on computer media, for capturing, storing, processing, evaluating and reproducing medical and pharmaceutical data

Providing temporary use of non-downloadable artificial intelligence computer programs on data networks for data analysis for use in the life sciences research field, pharmaceutical research, medical research, and drug discovery and development; platforms for artificial intelligence as software as a service (SaaS), namely, platform as a service (PAAS) featuring computer software platforms using artificial intelligence for data analysis for use in the life sciences research field, pharmaceutical research, medical research, and drug discovery and development; software as a service (SaaS) services featuring computer software platforms for data analysis for artificial intelligence for use in the life sciences research field, pharmaceutical research, medical research, and drug discovery and development; software as a service (SaaS) services featuring software for data analysis for use in the life sciences research field, pharmaceutical research, medical research, and drug discovery and development; software as a service (SaaS) services featuring artificial intelligence software for data analysis for use in the life sciences research field, pharmaceutical research, medical research, and drug discovery and development; software as a service (SaaS) services featuring artificial intelligence software for healthcare for capturing, storing, processing, evaluating and reproducing medical and pharmaceutical data; software as a service (SaaS) services featuring artificial intelligence software for data analysis; software as a service (SaaS) services featuring software using artificial intelligence for machine learning for healthcare; software as a service (SaaS) services featuring health monitoring software for monitoring health data; software as a service (SaaS) services featuring software relating to the medical field for controlling and managing patient medical information; software as a service (SaaS) services featuring bioinformatics software for drug discovery and development, for controlling and managing patient medical information; providing temporary use of non-downloadable software for capturing, storing, processing, evaluating and reproducing medical and pharmaceutical data; computer programming in the medical field; scientific computer programming services; artificial intelligence technology consultancy; research in the field of artificial intelligence; pharmaceutical research services; pharmaceutical products development; pharmaceutical product evaluation; research of pharmaceuticals; testing of pharmaceuticals; research relating to pharmaceuticals; development of gene-based medicines; conducting clinical trials for others for pharmaceutical products; laboratory research services relating to pharmaceuticals; consultancy in the field of pharmaceutical research; services for assessing the efficiency of pharmaceuticals, namely, testing of pharmaceuticals, pharmaceutical research and development; information technology services for the pharmaceutical and healthcare industries, namely information technology consultancy relating to installation, maintenance and repair of computer software; conducting early evaluations in the field of new pharmaceuticals, namely, testing of pharmaceuticals; providing information about pharmaceutical research, namely, the results of clinical trials for pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; chemical research and analysis services; medical and pharmacological research services; scientific research for medical purposes; drug discovery services; medical and scientific research, namely, conducting clinical trials for others; genetic research, namely, providing scientific research information in the field of genetics, providing medical research information in the field of genetics; genetic mapping for scientific purposes; providing scientific information in the field of medical disorders and their treatment

Pharmaceutical services, namely, pharmaceutical compounding, pharmaceutical advice; pharmaceutical consultation; pharmaceutical advisory services; provision of pharmaceutical information, namely, providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical services; medical consultancy services; medical advisory services; medical evaluation services, namely, medical testing for fitness evaluation, medical evaluation of cancer, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and conditions, conducting medical physical evaluations; medical diagnostic services; medical examination services; services for the provision of medical care information, namely, providing medical care information, providing medical care information via a website; medical services for the diagnosis of conditions of the human body; medical services for the treatment of conditions of the human body; medical care and analysis services relating to patient treatment; medical screening; drug screening for medical purposes; genetic testing for medical purposes

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Nov 14, 2025 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Oct 10, 2025 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Sep 22, 2025 FICS
FINAL DISPOSITION PROCESSED
Sep 22, 2025 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jun 11, 2025 FICR
NEW REPRESENTATIVE AT IB RECEIVED
Mar 28, 2025 NREP
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Mar 11, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Mar 11, 2025 R.PR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Feb 15, 2025 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jan 27, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Jan 26, 2025 OPNR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Dec 19, 2024 ERRR
CHANGE OF NAME/ADDRESS REC'D FROM IB
Nov 8, 2024 ADCH
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 17, 2024 NPUB
PUBLISHED FOR OPPOSITION
Sep 17, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 28, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 13, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Aug 13, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Aug 13, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Aug 13, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Aug 13, 2024 CNEA
NOTIFICATION OF FINAL REFUSAL EMAILED
Jun 29, 2024 GNFN
FINAL REFUSAL E-MAILED
Jun 29, 2024 GNFR
FINAL REFUSAL WRITTEN
Jun 29, 2024 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
May 24, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 24, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 24, 2024 TROA
REFUSAL PROCESSED BY IB
May 8, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Apr 17, 2024 RFCS
REFUSAL PROCESSED BY MPU
Apr 17, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 29, 2024 RFCR
NON-FINAL ACTION WRITTEN
Mar 28, 2024 CNRT
ASSIGNED TO EXAMINER
Mar 27, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Sep 12, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 7, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Aug 31, 2023 REPR